Short Term trading, analysis and TLX noise - No investors keep out, page-390

Speaking of which - imagine the powerhouse that would be venturing with the likes of Google Deepmind’s Isomorphic, Owkin, Sanofi, FormationBio, Insilinco (see below)… brave new world ahead, as soon as we’re able to identify new targets right away and without the heavy costs before AI!!

https://www.futuremedicine.com/doi/10.2217/fmai-2023-0019

4 March 2024

AI-enabled cancer target prioritization with optimal profiles balancing novelty, confidence and commercial tractability

The identification of new biological targets is crucial to advance cancer therapy, but deciphering the fiendishly complex processes that drive and sustain disease can be tedious and resource intensive. To optimize and accelerate the drug discovery process, artificial intelligence (AI) platforms are emerging that enable fast and cost-effective identification and prioritization of novel and disease-specific therapeutic targets with optimal target profiles, balancing confidence, novelty and commercial tractability. AI-streamlined target profiling has the potential to significantly improve the commercial burden of traditional drug development, and provides an unbiased approach for novel target identification. Here, we discuss the AI-assessed target profile and clinical relevance of genes recently identified by our AI-driven target discovery platform as top priority cancer targets.

https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-partners-with-openai-formation-bio-ai-driven-drug-development-2024-05-21/

21 May 2024

Sanofi partners with OpenAI, Formation Bio on AI-driven drug development

Sanofi said in a statement that the partnership with OpenAi will allow it to access proprietary data to develop AI models for its biopharma models, while Formation Bio will provide additional engineering resources. Major drugmakers are using artificial intelligence to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, both accelerating drug development and potentially saving millions of dollars.